December 15th, 2015

Company Update: Biogen Idec Inc. (NASDAQ:BIIB) – Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A

[Business Wire] – Today Biogen Idec and Swedish Orphan Biovitrum AB announced that the detailed phase 3 data for the companies’ investigational long-lasting recombinant factor VIII Fc fusion protein candidate ELOCTATE™ were published . . . → Read More: Company Update: Biogen Idec Inc. (NASDAQ:BIIB) – Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A Similar posts: MasterCard Incorporated (NYSE:MA) – MasterCard enters into agreement to acquire Provus – the leading independent Turkish payment solutions provider Demand for safety as Japan’s ratings cut to AA- Asian Session: Chinese manufacturing data encourages while Japanese jobless data inline with expectations.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.